A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Incyte Corporation
City of Hope Medical Center
University of Nebraska
M.D. Anderson Cancer Center
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Barbara Ann Karmanos Cancer Institute
Baylor College of Medicine
Bambino Gesù Hospital and Research Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center